Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Mon, 13.11.2023
Mainz BioMed N.V.
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
BERKELEY, US – MAINZ, Germany – NOVEMBER 13, 2023 — Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a securities purchase agree [ … ]
Thu, 09.11.2023
Mainz BioMed N.V.
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing
BERKELEY, US – MAINZ, Germany – NOVEMBER 9, 2023 — Mainz Biomed NV (NASDAQ:MYNZ [ … ]
Tue, 07.11.2023
Mainz BioMed N.V.
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
BERKELEY, US – MAINZ, Germany – NOVEMBER 7, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that VP Commercial Operations, Tarrin Khairi-Ta [ … ]
Tue, 31.10.2023
Mainz BioMed N.V.
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test.
BERKELEY, US – MAINZ, Germany – Octo [ … ]
Thu, 26.10.2023
Mainz BioMed N.V.
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region
BERKELEY, US – MAINZ, Germany – October 26, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a mole [ … ]
Wed, 18.10.2023
Mainz BioMed N.V.
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
Results indicate a substantial and meaningful enhancement in the effectiveness of non-invasive colorectal cancer (CRC) screening, particularly for the detection of advanced adenomas, a precursor to CRC
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensit [ … ]
Wed, 11.10.2023
Mainz BioMed N.V.
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92
BERKELEY, US – MAINZ, Germany – October 11, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnost [ … ]
Thu, 05.10.2023
Mainz BioMed N.V.
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
BERKELEY, US – MAINZ, Germany – October 5, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will attend the Jones [ … ]
Wed, 04.10.2023
Mainz BioMed N.V.
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population
BERKELEY, US – MAINZ, Germany – OCTOBER 4, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagn [ … ]
Wed, 27.09.2023
Mainz BioMed N.V.
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81%
Pulsus Group’s 4th International Conference on Gastroent [ … ]